Biological and clinical importance of the p53 tumor suppressor gene

Clinical Chemistry

Volumn 42, Issue 6 SUPPL., 1996, Pages 858-868

  Velculescu, Victor E ^a   El Deiry, Wafik S ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Bax; Cancer; Cell cycle; Chemoresistance; Cyclin; Cyclin dependent kinases; DNA damage, mutation; GADD45; Heritable disorders; Immunohistochemistry; Li Fraumeni syndrome; MDM2; Oncogenes; P21WAF1 CIP1; Radioresistance; SDI1

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER GENETICS; CELL GROWTH; DNA DAMAGE; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; GENE THERAPY; GENES, P53; HUMANS; MUTATION; NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029888514     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.6.858     Document Type: Article

References (18)

1. Vogelstein B. A deadly inheritance. Nature 1990;348:681-2.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
3. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249:912-5.
4. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250: 1233-8.
5. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990;348:747-9.
6. Kastan MB, Onyerkwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;53:6304-11.
7. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A 1992;89:4495-9.
8. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-35.
9. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-48.
10. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, et al. A p53-dependent mouse spindle checkpoint. Science 1995;267:1353-6.
11. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1995;266:1821-8.
12. Lane DP. p53, guardian of the genome. Nature 1992;358:15-6.
13. Koshland DE. Molecule of the year [Editorial]. Science 1993; 262:1953.
14. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366: 701-4.
15. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
16. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
17. Noda A, Ning Y, Venable SF, Pereira-Smit OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211:90-8.
18. Gu Y, Turck CW, Morgan DO. Inhibition of cdk2 activity in vivo by an associated 20K regulatory subunit. Nature 1993;366:707-10.